{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T03:24:33Z","timestamp":1788492273252,"version":"build-2803163510"},"reference-count":48,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Science and Technology Council","award":["MOST 111-2320-B-039-035-MY3"],"award-info":[{"award-number":["MOST 111-2320-B-039-035-MY3"]}]},{"name":"National Science and Technology Council","award":["NSTC 113-2321-B-039-004"],"award-info":[{"award-number":["NSTC 113-2321-B-039-004"]}]},{"name":"National Science and Technology Council","award":["NSTC 113-2320-B-039-043"],"award-info":[{"award-number":["NSTC 113-2320-B-039-043"]}]},{"name":"National Science and Technology Council","award":["CMU113-MF-51"],"award-info":[{"award-number":["CMU113-MF-51"]}]},{"name":"National Science and Technology Council","award":["CMU113-MF-71"],"award-info":[{"award-number":["CMU113-MF-71"]}]},{"name":"China Medical University","award":["MOST 111-2320-B-039-035-MY3"],"award-info":[{"award-number":["MOST 111-2320-B-039-035-MY3"]}]},{"name":"China Medical University","award":["NSTC 113-2321-B-039-004"],"award-info":[{"award-number":["NSTC 113-2321-B-039-004"]}]},{"name":"China Medical University","award":["NSTC 113-2320-B-039-043"],"award-info":[{"award-number":["NSTC 113-2320-B-039-043"]}]},{"name":"China Medical University","award":["CMU113-MF-51"],"award-info":[{"award-number":["CMU113-MF-51"]}]},{"name":"China Medical University","award":["CMU113-MF-71"],"award-info":[{"award-number":["CMU113-MF-71"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nutrients"],"abstract":"<jats:p>Background\/Objectives: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease worldwide, contributing to metabolic dysfunction and increased healthcare costs. The green Mediterranean diet reduces intrahepatic fat and elevates the plasma levels of 2,5-dihydroxybenzoic acid (2,5-DHBA), suggesting a mechanistic role for 2,5-DHBA in hepatic lipid metabolism. This study aimed to evaluate the therapeutic potential of 2,5-DHBA in MASLD and elucidate its molecular mechanism. Methods: Lipid accumulation was assessed in oleic acid-treated HepG2 cells and a high-fat diet (HFD)-induced MASLD mouse model. RNA sequencing, molecular docking, and immunohistochemical staining were performed to investigate the molecular mechanisms, focusing on the chemokine (C-C motif) ligand 2 (CCL2)\u2013CCL2 receptor (CCR2) axis. Results: 2,5-DHBA significantly reduced hepatic lipid accumulation in both HepG2 cells and HFD-fed mice in a dose-dependent manner. RNA sequencing revealed the marked downregulation of CCL2, a key proinflammatory mediator in MASLD pathogenesis. Molecular docking predicted that 2,5-DHBA competed with CCL2 for binding at the CCR2 axis. Immunohistochemistry further confirmed that 2,5-DHBA treatment lowered hepatic CCL2 expression, suppressed nuclear factor-\u03baB activation, and reduced inflammatory cell infiltration. These findings suggest that 2,5-DHBA exerted anti-steatotic effects by modulating the CCL2-CCR2 signaling pathway. Conclusions: This is the first study to demonstrate that 2,5-DHBA attenuates hepatic steatosis via targeting the CCL2-CCR2 axis. These findings highlight its potential as a novel nutraceutical strategy for MASLD treatment.<\/jats:p>","DOI":"10.3390\/nu17111835","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T08:12:47Z","timestamp":1748419967000},"page":"1835","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["2,5-Dihydroxybenzoic Acid Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Targeting the CCL2-CCR2 Axis to Reduce Lipid Accumulation"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6507-8015","authenticated-orcid":false,"given":"Chien-Yun","family":"Hsiang","sequence":"first","affiliation":[{"name":"Department of Microbiology and Immunology, China Medical University, Taichung 404333, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuang-Ting","family":"Hsu","sequence":"additional","affiliation":[{"name":"School of Medicine, China Medical University, Taichung 404333, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Yi","family":"Lo","sequence":"additional","affiliation":[{"name":"Graduate Institute of Chinese Medicine, China Medical University, Taichung 404333, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Jhu","family":"Hou","sequence":"additional","affiliation":[{"name":"Department of Animal Science and Technology, National Taiwan University, Taipei 106319, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2390-1461","authenticated-orcid":false,"given":"Tin-Yun","family":"Ho","sequence":"additional","affiliation":[{"name":"Graduate Institute of Chinese Medicine, China Medical University, Taichung 404333, Taiwan"},{"name":"Department of Health and Nutrition Biotechnology, Asia University, Taichung 413305, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/S2468-1253(24)00193-6","article-title":"Natural history and progression of metabolic dysfunction-associated steatotic liver disease","volume":"9","author":"Shang","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41572-025-00599-1","article-title":"Metabolic dysfunction-associated steatotic liver disease in adults","volume":"11","author":"Huang","year":"2025","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Jurek, J.M., Zablocka-Sowinska, K., Clavero Mestres, H., Reyes Guti\u00e9rrez, L., Camaron, J., and Auguet, T. (2025). The impact of dietary interventions on metabolic outcomes in metabolic dysfunction-associated steatotic liver disease (MASLD) and comorbid conditions, including obesity and type 2 diabetes. Nutrients, 17.","DOI":"10.3390\/nu17071257"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S244","DOI":"10.3350\/cmh.2022.0364","article-title":"Eating, diet, and nutrition for the treatment of non-alcoholic fatty liver disease","volume":"29","author":"Semmler","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/s41430-023-01335-2","article-title":"Fatty acid composition but not quantity is an important indicator of non-alcoholic fatty liver disease: A systematic review","volume":"77","author":"Das","year":"2023","journal-title":"Eur. J. Clin. Nutr."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1017\/S0007114522003956","article-title":"Association between ultra-processed foods consumption and risk of non-alcoholic fatty liver disease: A population-based analysis of NHANES 2011-2018","volume":"130","author":"Liu","year":"2023","journal-title":"Br. J. Nutr."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Mercurio, G., Giacco, A., Scopigno, N., Vigliotti, M., Goglia, F., Cioffi, F., and Silvestri, E. (2025). Mitochondria at the crossroads: Linking the Mediterranean diet to metabolic health and non-pharmacological approaches to NAFLD. Nutrients, 17.","DOI":"10.3390\/nu17071214"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/nbu.12707","article-title":"Mediterranean diet for the management of metabolic dysfunction-associated steatotic liver disease in non-Mediterranean, Western countries: What\u2019s known and what\u2019s needed?","volume":"49","author":"Sualeheen","year":"2024","journal-title":"Nutr. Bull."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"8248","DOI":"10.1039\/D4FO01461H","article-title":"A systematic review and meta-analysis of randomized controlled trials: Effects of mediterranean diet and low-fat diet on liver enzymes and liver fat content of NAFLD","volume":"15","author":"Xiong","year":"2024","journal-title":"Food Funct."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Berisha, H., Hattab, R., Comi, L., Giglione, C., Migliaccio, S., and Magni, P. (2025). Nutrition and lifestyle interventions in managing dyslipidemia and cardiometabolic risk. Nutrients, 17.","DOI":"10.3390\/nu17050776"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Bonofiglio, D. (2025). Effects of Mediterranean diet on chronic degenerative diseases and human healthy lifestyle. Nutrients, 17.","DOI":"10.3390\/nu17071231"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejim.2023.11.012","article-title":"Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease","volume":"122","author":"Haldrup","year":"2024","journal-title":"Eur. J. Intern. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.ajcnut.2023.11.013","article-title":"Effect of an Asian-adapted Mediterranean diet and pentadecanoic acid on fatty liver disease: The TANGO randomized controlled trial","volume":"119","author":"Chooi","year":"2024","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.clnu.2013.08.014","article-title":"Adherence to the Mediterranean diet is associated with the severity of non-alcoholic fatty liver disease","volume":"33","author":"Kontogianni","year":"2014","journal-title":"Clin. Nutr."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1136\/gutjnl-2020-323106","article-title":"Effect of green-Mediterranean diet on intrahepatic fat: The DIRECT PLUS randomised controlled trial","volume":"70","author":"Rinott","year":"2021","journal-title":"Gut"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/ptr.6573","article-title":"A review on gentisic acid as a plant derived phenolic acid and metabolite of aspirin: Comprehensive pharmacology, toxicology, and some pharmaceutical aspects","volume":"34","author":"Abedi","year":"2020","journal-title":"Phytother. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1039\/D0FO02474K","article-title":"Gentisic acid prevents diet-induced obesity in mice by accelerating the thermogenesis of brown adipose tissue","volume":"12","author":"Han","year":"2021","journal-title":"Food Funct."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1039\/D1FO02788C","article-title":"A gastro-resistant peptide from Momordica charantia improves diabetic nephropathy in db\/db mice via its novel reno-protective and anti-inflammatory activities","volume":"13","author":"Liao","year":"2022","journal-title":"Food Funct."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"W234","DOI":"10.1093\/nar\/gkz240","article-title":"NetworkAnalyst 3.0: A visual analytics platform for comprehensive gene expression profiling and meta-analysis","volume":"47","author":"Zhou","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"W363","DOI":"10.1093\/nar\/gki481","article-title":"PatchDock and SymmDock: Servers for rigid and symmetric docking","volume":"33","author":"Inbar","year":"2005","journal-title":"Nucleic Acids Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1021\/acs.jcim.5b00559","article-title":"ZINC 15-ligand discovery for everyone","volume":"55","author":"Sterling","year":"2015","journal-title":"J. Chem. Inf. Model."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e4792","DOI":"10.1002\/pro.4792","article-title":"UCSF ChimeraX: Tools for structure building and analysis","volume":"32","author":"Meng","year":"2023","journal-title":"Protein Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1039\/D0FO02736G","article-title":"Hesperetin ameliorates hepatic oxidative stress and inflammation via the PI3K\/AKT-Nrf2-ARE pathway in oleic acid-induced HepG2 cells and a rat model of high-fat diet-induced NAFLD","volume":"12","author":"Li","year":"2021","journal-title":"Food Funct."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1476-5381.1953.tb00745.x","article-title":"Investigation in vivo of new inhibitors of hyaluronidase","volume":"8","author":"Hahn","year":"1953","journal-title":"Br. J. Pharmacol. Chemother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrgastro.2010.191","article-title":"Animal models of nonalcoholic fatty liver disease","volume":"8","author":"Hebbard","year":"2011","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2010.04.031","article-title":"Hepatocellular ballooning in NASH","volume":"53","author":"Caldwell","year":"2010","journal-title":"J. Hepatol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Rafaqat, S., Gluscevic, S., Mercantepe, F., Rafaqat, S., and Klisic, A. (2024). Interleukins: Pathogenesis in non-alcoholic fatty liver disease. Metabolites, 14.","DOI":"10.3390\/metabo14030153"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41421-022-00403-4","article-title":"Molecular insights into ligand recognition and activation of chemokine receptors CCR2 and CCR3","volume":"8","author":"Shao","year":"2022","journal-title":"Cell Discov."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Nagata, N., Chen, G., Xu, L., and Ando, H. (2022). An update on the chemokine system in the development of NAFLD. Medicina, 58.","DOI":"10.20944\/preprints202205.0252.v1"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Pan, X., Chiwanda Kaminga, A., Liu, A., Wen, S.W., Chen, J., and Luo, J. (2020). Chemokines in non-alcoholic fatty liver disease: A systematic review and network meta-analysis. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.01802"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/978-981-10-8684-7_4","article-title":"Chemokines and chemokine receptors in the development of NAFLD","volume":"1061","author":"Roh","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Steinberg, G.R., Valvano, C.M., De Nardo, W., and Watt, M.J. (J. Hepatol., 2025). Integrative metabolism in MASLD and MASH: Pathophysiology and emerging mechanisms, J. Hepatol., in press.","DOI":"10.1016\/j.jhep.2025.02.033"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3892\/ijmm.2024.5412","article-title":"Current strategies for nonalcoholic fatty liver disease treatment","volume":"54","author":"Sun","year":"2024","journal-title":"Int. J. Mol. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S2468-1253(23)00159-0","article-title":"NASH drug treatment development: Challenges and lessons","volume":"8","author":"Tilg","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"103910","DOI":"10.1016\/j.drudis.2024.103910","article-title":"NAFLD and NASH: Etiology, targets and emerging therapies","volume":"29","author":"Wei","year":"2024","journal-title":"Drug Discov. Today"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"G483","DOI":"10.1152\/ajpgi.00213.2017","article-title":"CC chemokine receptor 2 promotes recruitment of myeloid cells associated with insulin resistance in nonalcoholic fatty liver disease","volume":"314","author":"Parker","year":"2018","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1136\/gutjnl-2011-300304","article-title":"Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury","volume":"61","author":"Baeck","year":"2012","journal-title":"Gut"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1158\/1535-7163.MCT-16-0124","article-title":"Blocking the CCL2-CCR2 axis using CCL2-neutralizing antibody is an effective therapy for hepatocellular cancer in a mouse model","volume":"16","author":"Teng","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2147\/CEG.S329424","article-title":"Activation and functional priming of blood neutrophils in non-alcoholic fatty liver disease increases in non-alcoholic steatohepatitis","volume":"14","author":"Lauszus","year":"2021","journal-title":"Clin. Exp. Gastroenterol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.cgh.2021.11.026","article-title":"Systematic review and meta-analysis: The role of diet in the development of nonalcoholic fatty liver disease","volume":"21","author":"Tsompanaki","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Comi, L., Giglione, C., Tolaj Klinaku, F., Da Dalt, L., Ullah, H., Daglia, M., and Magni, P. (2025). Evaluation of metabolic dysfunction-associated fatty liver disease-related pathogenic mechanisms in human steatotic liver cell-based model: Beneficial effects of Prunus domestica L. subsp. syriaca extract. Nutrients, 17.","DOI":"10.3390\/nu17071249"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Abe, T. (2025). Isoschaftoside in fig leaf tea alleviates nonalcoholic fatty liver disease in mice via the regulation of macrophage polarity. Nutrients, 17.","DOI":"10.3390\/nu17050757"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Kim, Y.J., Park, S., Kim, H., Kim, S.R., and Jung, U.J. (2025). Myricitrin alleviates hypercholesterolemia and non-alcoholic fatty liver disease in high cholesterol diet-fed mice. Nutrients, 17.","DOI":"10.3390\/nu17030415"},{"key":"ref_46","first-page":"9067","article-title":"Tea polyphenol epigallocatechin gallate protects against nonalcoholic fatty liver disease and associated endotoxemia in rats via modulating gut microbiota dysbiosis and alleviating intestinal barrier dysfunction and related inflammation","volume":"72","author":"Zuo","year":"2024","journal-title":"J. Agric. Food Chem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1021\/acs.jafc.2c08169","article-title":"Millet bran protein hydrolysate displays the anti-non-alcoholic fatty liver disease effect via activating peroxisome proliferator-activated receptor \u03b3 to restrain fatty acid uptake","volume":"71","author":"Shan","year":"2023","journal-title":"J. Agric. Food Chem."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Chiu, W.C., Yang, H.H., Chiang, S.C., Chou, Y.X., and Yang, H.T. (2014). Auricularia polytricha aqueous extract supplementation decreases hepatic lipid accumulation and improves antioxidative status in animal model of nonalcoholic fatty liver. Biomedicine, 4.","DOI":"10.7603\/s40681-014-0012-3"}],"container-title":["Nutrients"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6643\/17\/11\/1835\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:42:14Z","timestamp":1760031734000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6643\/17\/11\/1835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":48,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["nu17111835"],"URL":"https:\/\/doi.org\/10.3390\/nu17111835","relation":{},"ISSN":["2072-6643"],"issn-type":[{"value":"2072-6643","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,28]]}}}